NO323305B1 - Opploselig rekombinant botulinum-toksin og farmasoytisk preparat som inneholder det. - Google Patents
Opploselig rekombinant botulinum-toksin og farmasoytisk preparat som inneholder det. Download PDFInfo
- Publication number
- NO323305B1 NO323305B1 NO19971868A NO971868A NO323305B1 NO 323305 B1 NO323305 B1 NO 323305B1 NO 19971868 A NO19971868 A NO 19971868A NO 971868 A NO971868 A NO 971868A NO 323305 B1 NO323305 B1 NO 323305B1
- Authority
- NO
- Norway
- Prior art keywords
- protein
- toxin
- phisbot
- soluble
- botulinum
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title claims description 23
- 229940053031 botulinum toxin Drugs 0.000 title claims description 20
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 4
- 231100000765 toxin Toxicity 0.000 claims abstract description 141
- 239000003053 toxin Substances 0.000 claims abstract description 140
- 210000004027 cell Anatomy 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 39
- 241000588724 Escherichia coli Species 0.000 claims description 26
- 229920002704 polyhistidine Polymers 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 239000003398 denaturant Substances 0.000 claims description 6
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 210000000805 cytoplasm Anatomy 0.000 claims description 4
- 239000003599 detergent Substances 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 abstract description 152
- 230000001147 anti-toxic effect Effects 0.000 abstract description 107
- 239000007787 solid Substances 0.000 abstract description 32
- 229960005486 vaccine Drugs 0.000 abstract description 32
- 241000193163 Clostridioides difficile Species 0.000 abstract description 29
- 241001465754 Metazoa Species 0.000 abstract description 26
- 238000011282 treatment Methods 0.000 abstract description 22
- 231100000699 Bacterial toxin Toxicity 0.000 abstract description 19
- 239000000688 bacterial toxin Substances 0.000 abstract description 19
- 230000001225 therapeutic effect Effects 0.000 abstract description 17
- 239000002702 enteric coating Substances 0.000 abstract description 16
- 238000009505 enteric coating Methods 0.000 abstract description 16
- 230000003472 neutralizing effect Effects 0.000 abstract description 16
- 241000271566 Aves Species 0.000 abstract description 12
- 239000007864 aqueous solution Substances 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 description 364
- 102000004169 proteins and genes Human genes 0.000 description 341
- 235000018102 proteins Nutrition 0.000 description 338
- 239000012634 fragment Substances 0.000 description 94
- 102000037865 fusion proteins Human genes 0.000 description 73
- 108020001507 fusion proteins Proteins 0.000 description 73
- 241000193155 Clostridium botulinum Species 0.000 description 66
- 239000002953 phosphate buffered saline Substances 0.000 description 63
- 241000699670 Mus sp. Species 0.000 description 57
- 238000002360 preparation method Methods 0.000 description 57
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 54
- 239000000243 solution Substances 0.000 description 51
- 239000002158 endotoxin Substances 0.000 description 47
- 230000014509 gene expression Effects 0.000 description 47
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 47
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 42
- 108010001160 IgY Proteins 0.000 description 41
- 239000000499 gel Substances 0.000 description 41
- 210000002966 serum Anatomy 0.000 description 38
- 239000011347 resin Substances 0.000 description 37
- 229920005989 resin Polymers 0.000 description 37
- 238000000746 purification Methods 0.000 description 35
- 239000000872 buffer Substances 0.000 description 29
- 208000003508 Botulism Diseases 0.000 description 28
- 239000011780 sodium chloride Substances 0.000 description 28
- 239000000203 mixture Substances 0.000 description 27
- 241000700159 Rattus Species 0.000 description 25
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 25
- 101710182532 Toxin a Proteins 0.000 description 25
- 239000013612 plasmid Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 241001509421 Clostridium botulinum C Species 0.000 description 23
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 23
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 23
- 230000027455 binding Effects 0.000 description 23
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 238000004519 manufacturing process Methods 0.000 description 21
- 239000008188 pellet Substances 0.000 description 21
- 239000013598 vector Substances 0.000 description 21
- 230000003053 immunization Effects 0.000 description 20
- 238000002649 immunization Methods 0.000 description 19
- 230000004927 fusion Effects 0.000 description 18
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 18
- 239000007788 liquid Substances 0.000 description 18
- 238000010790 dilution Methods 0.000 description 17
- 239000012895 dilution Substances 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 238000005119 centrifugation Methods 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 239000006166 lysate Substances 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 241000282412 Homo Species 0.000 description 14
- 229920001213 Polysorbate 20 Polymers 0.000 description 14
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 239000012148 binding buffer Substances 0.000 description 14
- 229940098773 bovine serum albumin Drugs 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 14
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 238000010276 construction Methods 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 229940027941 immunoglobulin g Drugs 0.000 description 12
- 239000002510 pyrogen Substances 0.000 description 12
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 230000002163 immunogen Effects 0.000 description 11
- 239000002581 neurotoxin Substances 0.000 description 11
- 238000006386 neutralization reaction Methods 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 101710138657 Neurotoxin Proteins 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 10
- 210000002969 egg yolk Anatomy 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 201000011422 infant botulism Diseases 0.000 description 10
- 231100000618 neurotoxin Toxicity 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 108010074860 Factor Xa Proteins 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 208000034972 Sudden Infant Death Diseases 0.000 description 9
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 231100001102 clostridial toxin Toxicity 0.000 description 9
- 235000013601 eggs Nutrition 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 210000003000 inclusion body Anatomy 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 238000007912 intraperitoneal administration Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 235000015097 nutrients Nutrition 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 241001112695 Clostridiales Species 0.000 description 8
- 102000004594 DNA Polymerase I Human genes 0.000 description 8
- 108010017826 DNA Polymerase I Proteins 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000012539 chromatography resin Substances 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 238000007911 parenteral administration Methods 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 229920000856 Amylose Polymers 0.000 description 7
- 239000012480 LAL reagent Substances 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 102000002933 Thioredoxin Human genes 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 238000011109 contamination Methods 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 210000000936 intestine Anatomy 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 108060008226 thioredoxin Proteins 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 229920003134 Eudragit® polymer Polymers 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 6
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 6
- 238000001261 affinity purification Methods 0.000 description 6
- 235000013330 chicken meat Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000001665 lethal effect Effects 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 241000193403 Clostridium Species 0.000 description 5
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- 108010040201 Polymyxins Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 235000017550 sodium carbonate Nutrition 0.000 description 5
- 238000005063 solubilization Methods 0.000 description 5
- 230000007928 solubilization Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 108091006054 His-tagged proteins Proteins 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 231100000566 intoxication Toxicity 0.000 description 4
- 230000035987 intoxication Effects 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 238000012454 limulus amebocyte lysate test Methods 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- QWVRTSZDKPRPDF-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2h-1,2,4-oxadiazine Chemical compound C1CCCCN1CC(N=1)CONC=1C1=CC=CN=C1 QWVRTSZDKPRPDF-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 108010042653 IgA receptor Proteins 0.000 description 3
- 238000011050 LAL assay Methods 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000002320 anti-botulinal effect Effects 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 238000011082 depyrogenation Methods 0.000 description 3
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 231100000636 lethal dose Toxicity 0.000 description 3
- 235000021056 liquid food Nutrition 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 244000005706 microflora Species 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000005588 protonation Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012723 sample buffer Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229940033663 thimerosal Drugs 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000271533 Crotalus durissus terrificus Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000015725 Inhalational botulism Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000006149 azo coupling reaction Methods 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000005447 environmental material Substances 0.000 description 2
- 239000002095 exotoxin Substances 0.000 description 2
- 231100000776 exotoxin Toxicity 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 201000011424 foodborne botulism Diseases 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229910001453 nickel ion Inorganic materials 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000012803 optimization experiment Methods 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000011046 pyrogen test Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- -1 steroid compounds Chemical class 0.000 description 2
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 201000011423 wound botulism Diseases 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- IFJIRCKGJYDCAE-UHFFFAOYSA-N (5-bromo-3-chloro-1H-indol-2-yl) dihydrogen phosphate Chemical compound C1=C(Br)C=C2C(Cl)=C(OP(O)(=O)O)NC2=C1 IFJIRCKGJYDCAE-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- 208000032484 Accidental exposure to product Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000486679 Antitype Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 206010061043 Clostridial infection Diseases 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 201000000628 Gas Gangrene Diseases 0.000 description 1
- 206010017898 Gastroenteritis clostridial Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000032754 Infant Death Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 238000003231 Lowry assay Methods 0.000 description 1
- 238000009013 Lowry's assay Methods 0.000 description 1
- 101150028955 MBP gene Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- PIJXCSUPSNFXNE-QRZOAFCBSA-N N-acetyl-4-(N-acetylglucosaminyl)muramoyl-L-alanyl-D-isoglutamine Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@@H](NC(C)=O)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 PIJXCSUPSNFXNE-QRZOAFCBSA-N 0.000 description 1
- 241001460678 Napo <wasp> Species 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000033952 Paralysis flaccid Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 231100000818 accidental exposure Toxicity 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100001133 acute intoxication condition Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108091006055 affinity-tagged proteins Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 208000020936 anaerobic cellulitis Diseases 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002303 anti-venom Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000003131 biological toxin Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000003618 borate buffered saline Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000004395 cytoplasmic granule Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 230000007893 endotoxin activity Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000028331 flaccid paralysis Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000004763 spore germination Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32915494A | 1994-10-24 | 1994-10-24 | |
US08/405,496 US5919665A (en) | 1989-10-31 | 1995-03-16 | Vaccine for clostridium botulinum neurotoxin |
US42271195A | 1995-04-14 | 1995-04-14 | |
US08/480,604 US5736139A (en) | 1989-10-31 | 1995-06-07 | Treatment of Clostridium difficile induced disease |
PCT/US1995/013737 WO1996012802A1 (en) | 1989-10-31 | 1995-10-23 | Vaccine and antitoxin for treatment and prevention of c. difficile disease |
Publications (3)
Publication Number | Publication Date |
---|---|
NO971868D0 NO971868D0 (no) | 1997-04-23 |
NO971868L NO971868L (no) | 1997-06-24 |
NO323305B1 true NO323305B1 (no) | 2007-03-05 |
Family
ID=27502393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19971868A NO323305B1 (no) | 1994-10-24 | 1997-04-23 | Opploselig rekombinant botulinum-toksin og farmasoytisk preparat som inneholder det. |
Country Status (17)
Country | Link |
---|---|
US (1) | US6290960B1 (cs) |
EP (2) | EP1041149B8 (cs) |
JP (2) | JP2002514886A (cs) |
CN (1) | CN1176658A (cs) |
AT (1) | ATE366312T1 (cs) |
AU (1) | AU709586B2 (cs) |
BR (1) | BR9509903A (cs) |
CA (1) | CA2203504A1 (cs) |
CZ (1) | CZ296806B6 (cs) |
DE (1) | DE69535530D1 (cs) |
FI (1) | FI971732A (cs) |
HU (1) | HUT78048A (cs) |
MX (1) | MX9702955A (cs) |
NO (1) | NO323305B1 (cs) |
NZ (2) | NZ337543A (cs) |
PL (1) | PL320214A1 (cs) |
WO (1) | WO1996012802A1 (cs) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7214787B1 (en) * | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
US8012491B2 (en) | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
WO1998008540A1 (en) * | 1996-08-28 | 1998-03-05 | Ophidian Pharmaceuticals, Inc. | Multivalent vaccine for clostridium botulinum neurotoxin |
CA2265887A1 (en) * | 1996-09-10 | 1998-03-19 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof |
US6036953A (en) * | 1996-11-29 | 2000-03-14 | The General Hospital Corporation | Heterologous antigens in live cell V. cholerae strains |
US7179611B2 (en) * | 1997-02-10 | 2007-02-20 | Bd Lee Laboratories | Mono-specific polyclonal antibodies and methods for detecting Clostridium difficile Toxin A |
EP1000155A1 (en) * | 1997-06-20 | 2000-05-17 | QUEEN MARY & WESTFIELD COLLEGE | Immunogenic fragments of toxin a of clostridium difficile |
DE19739685A1 (de) | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
DE69829400T2 (de) * | 1997-10-20 | 2006-04-13 | Acambis, Inc., Cambridge | Passive immunisierung gegen durch clostridium difficile verursachte krankheit |
US6051239A (en) * | 1997-10-20 | 2000-04-18 | Thomas Jefferson University | Compositions and methods for systemic delivery of oral vaccines and therapeutic agents |
US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
US6780617B2 (en) | 2000-12-29 | 2004-08-24 | Chen & Chen, Llc | Sample processing device and method |
WO2000002902A1 (en) * | 1998-07-13 | 2000-01-20 | Gill Parkash S | Novel inhibitors of angiogenesis and tumor growth |
US20040071736A1 (en) | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
GB9907429D0 (en) | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
US6733760B1 (en) | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
AU781175B2 (en) * | 1999-04-09 | 2005-05-12 | Intercell Usa, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium Difficile |
EP1057895A1 (de) * | 1999-06-04 | 2000-12-06 | Lohmann Animal Health GmbH & Co. KG | Fusionsprotein das das Fragment B des Shigatoxins enthält, dieses enthaltende (Impf-)Stoffzusammensetzung und Verfahren zu dessen Herstellung |
FR2796385A1 (fr) * | 1999-07-16 | 2001-01-19 | Inst Nat Sante Rech Med | Methode de production d'anticorps dans le jaune d'oeuf et utilisation des anticorps ainsi obtenus |
GB9921592D0 (en) | 1999-09-13 | 1999-11-17 | Microbiological Res Authority | Preparation of highly pure toxin fragments |
US20080038274A1 (en) | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
UA79735C2 (uk) | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах |
JP4513085B2 (ja) | 2001-09-11 | 2010-07-28 | アイキューム インク | 試料の容器 |
US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
ES2566509T3 (es) | 2003-02-05 | 2016-04-13 | Iquum, Inc. | Procesado de muestras |
US9701737B2 (en) * | 2003-02-19 | 2017-07-11 | Camas, Incorporated | Immunogen adherence and method of making and using same |
NZ548821A (en) | 2004-02-06 | 2009-12-24 | Univ Massachusetts | Antibodies against clostridium difficile toxins and uses thereof |
US20080057575A1 (en) * | 2004-08-04 | 2008-03-06 | Allergan, Inc. | Optimizing Expression of Active Botulinum Toxin Type A |
HUE028818T2 (en) | 2004-11-24 | 2017-01-30 | Techlab Inc | Tool and method for detecting analytes |
GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
WO2007146139A2 (en) * | 2006-06-08 | 2007-12-21 | Cornell Research Foundation, Inc. | Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b |
CN100564527C (zh) * | 2006-10-23 | 2009-12-02 | 中国人民解放军军事医学科学院生物工程研究所 | A型肉毒毒素受体结合区Hc基因及其编码蛋白与应用 |
JP5305427B2 (ja) * | 2007-01-11 | 2013-10-02 | 公立大学法人大阪府立大学 | インフルエンザウイルスに対する抗体の産生方法 |
JP2008169142A (ja) * | 2007-01-11 | 2008-07-24 | Osaka Prefecture Univ | 食中毒菌に対する抗体の産生方法 |
US9802988B2 (en) | 2009-05-20 | 2017-10-31 | University Of Maryland, Baltimore | Engineered type IV pilin of Clostridium difficile |
EP2432500A4 (en) | 2009-05-20 | 2014-03-26 | Univ Maryland | MANIPULATED TYPE IV PILIN OF CLOSTRIDIUM DIFFICILE |
CA2782406A1 (en) * | 2009-12-02 | 2011-06-09 | Tufts University | Atoxic recombinant holotoxins of clostridium difficile as immunogens |
GB0921288D0 (en) * | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
KR101907434B1 (ko) * | 2010-09-03 | 2018-10-12 | 발네바 오스트리아 게엠베하 | C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도 |
GB201016742D0 (en) * | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
CN102533867A (zh) * | 2010-12-10 | 2012-07-04 | 西北民族大学 | 一种艰难梭菌a毒素的类毒素的制备方法 |
CN102181457B (zh) * | 2011-03-21 | 2012-07-04 | 王世霞 | 密码子优化的艰难梭菌外毒素b氨基端基因序列及其核酸疫苗 |
TWI815599B (zh) | 2011-04-22 | 2023-09-11 | 美商惠氏有限責任公司 | 與難養芽胞梭菌(Clostridium difficile)之突變毒素有關之組成物及彼之方法 |
SI2714911T1 (sl) * | 2011-05-27 | 2017-03-31 | Glaxosmithkline Biologicals S.A. | Imunogeni sestavek |
WO2013082298A2 (en) * | 2011-11-30 | 2013-06-06 | Board Of Trustees Of Michigan State University | Immunological composition for clostridium difficile |
US9694063B2 (en) | 2011-12-08 | 2017-07-04 | Glaxosmithkline Biologicals Sa | Clostridium difficile toxin-based vaccine |
BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
HUE061273T2 (hu) | 2012-12-05 | 2023-06-28 | Glaxosmithkline Biologicals Sa | Immunogén készítmény |
CN103865938B (zh) * | 2012-12-16 | 2016-10-05 | 山东国际生物科技园发展有限公司 | 艰难梭菌外毒素a羧基端序列密码子优化基因片段、表达载体构建方法及其表达蛋白的应用 |
US9758838B2 (en) | 2013-03-12 | 2017-09-12 | Yale University | Compositions and methods for identifying secretory antibody-bound microbes |
BE1022949B1 (fr) | 2014-06-25 | 2016-10-21 | Glaxosmithkline Biologicals S.A. | Composition immunogene |
US10925953B2 (en) * | 2014-08-28 | 2021-02-23 | Yale University | Compositions and methods for treating an inflammatory disease or disorder |
AU2016274599B2 (en) | 2015-06-12 | 2021-09-02 | Vaxart, Inc. | Formulations for small intestinal delivery of RSV and norovirus antigens |
EP3362052A4 (en) * | 2015-10-16 | 2019-06-19 | Merck Sharp & Dohme Corp. | PROCESS FOR PREPARING FORMULATIONS FOR GASTROINTESTINAL THERAPIES |
JP6964623B2 (ja) * | 2017-03-29 | 2021-11-10 | バルネバ オーストリア ジーエムビーエイチ | C.ディフィシルの毒素aおよび毒素bタンパク質の単離ポリペプチドならびにその使用 |
JP6612807B2 (ja) * | 2017-03-29 | 2019-11-27 | バルネバ オーストリア ジーエムビーエイチ | C.ディフィシルの毒素aおよび毒素bタンパク質の単離ポリペプチドならびにその使用 |
CN108822211B (zh) * | 2018-06-05 | 2019-12-24 | 中国人民解放军军事科学院军事医学研究院 | 一种制备a、b、e、f型四价肉毒抗毒素的方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4550019A (en) * | 1978-03-22 | 1985-10-29 | South Africa Inventions Development Corporation | Manufacture and use of fowl egg antibodies |
CH0225254H1 (en) | 1985-11-25 | 1998-09-15 | Ghen Corp | Specific antibody-containing substance from eggs and method of production and use thereof |
US5831022A (en) * | 1986-02-18 | 1998-11-03 | Hoffmann-La Roche Inc. | Purification of recombinant human IL-1α |
CA1340522C (en) * | 1987-03-10 | 1999-05-04 | Heinz Dobeli | Fusion proteins containing neighbouring histidines for improved purification |
US5196193A (en) * | 1989-10-31 | 1993-03-23 | Ophidian Pharmaceuticals, Inc. | Antivenoms and methods for making antivenoms |
US5601823A (en) * | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
US5736139A (en) * | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
US5268295A (en) * | 1991-05-31 | 1993-12-07 | W. Alton Jones Cell Science Center, Inc. | Mammalian adipocyte protein p154, nucleic acids coding therefor and uses thereof |
GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
EP0659214A1 (en) * | 1992-09-01 | 1995-06-28 | Immulogic Pharmaceutical Corporation | Allergenic proteins and peptides from japanese cedar pollen |
JPH06192118A (ja) * | 1992-09-28 | 1994-07-12 | Wisconsin Alumni Res Found | ボツリヌス毒素を含む異常に過敏な筋運動障害の治療用薬剤組成物およびその製造方法 |
JPH06192296A (ja) * | 1992-10-28 | 1994-07-12 | Chiba Pref Gov | 治療用医薬品としての結晶a型ボツリヌス毒素の製造法。 |
US5480972A (en) * | 1992-10-30 | 1996-01-02 | The University Of Melbourne | Allergenic proteins from Johnson grass pollen |
-
1995
- 1995-10-23 CZ CZ0125097A patent/CZ296806B6/cs not_active IP Right Cessation
- 1995-10-23 EP EP00105371A patent/EP1041149B8/en not_active Expired - Lifetime
- 1995-10-23 AT AT00105371T patent/ATE366312T1/de not_active IP Right Cessation
- 1995-10-23 WO PCT/US1995/013737 patent/WO1996012802A1/en active IP Right Grant
- 1995-10-23 DE DE69535530T patent/DE69535530D1/de not_active Expired - Lifetime
- 1995-10-23 CN CN95196424A patent/CN1176658A/zh active Pending
- 1995-10-23 BR BR9509903A patent/BR9509903A/pt not_active Application Discontinuation
- 1995-10-23 JP JP51412796A patent/JP2002514886A/ja active Pending
- 1995-10-23 NZ NZ337543A patent/NZ337543A/en unknown
- 1995-10-23 PL PL95320214A patent/PL320214A1/xx unknown
- 1995-10-23 HU HU9901238A patent/HUT78048A/hu active IP Right Revival
- 1995-10-23 EP EP95937626A patent/EP0796326A4/en not_active Withdrawn
- 1995-10-23 CA CA002203504A patent/CA2203504A1/en not_active Abandoned
- 1995-10-23 NZ NZ295998A patent/NZ295998A/en unknown
- 1995-10-23 AU AU39683/95A patent/AU709586B2/en not_active Ceased
-
1997
- 1997-04-23 NO NO19971868A patent/NO323305B1/no unknown
- 1997-04-23 MX MX9702955A patent/MX9702955A/es unknown
- 1997-04-23 FI FI971732A patent/FI971732A/fi unknown
- 1997-08-20 US US08/915,136 patent/US6290960B1/en not_active Expired - Fee Related
-
2002
- 2002-08-20 JP JP2002238940A patent/JP3914484B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NZ337543A (en) | 2002-06-28 |
NO971868D0 (no) | 1997-04-23 |
HUT78048A (hu) | 1999-07-28 |
WO1996012802A1 (en) | 1996-05-02 |
NZ295998A (en) | 1999-10-28 |
CZ125097A3 (cs) | 1998-03-18 |
CZ296806B6 (cs) | 2006-06-14 |
US6290960B1 (en) | 2001-09-18 |
DE69535530D1 (de) | 2007-08-16 |
JP2003137897A (ja) | 2003-05-14 |
FI971732A0 (fi) | 1997-04-23 |
CN1176658A (zh) | 1998-03-18 |
EP0796326A4 (en) | 2000-01-19 |
FI971732A (fi) | 1997-06-23 |
WO1996012802A9 (en) | 1999-09-16 |
MX9702955A (es) | 1998-07-31 |
JP2002514886A (ja) | 2002-05-21 |
EP0796326A1 (en) | 1997-09-24 |
ATE366312T1 (de) | 2007-07-15 |
EP1041149B8 (en) | 2007-10-03 |
EP1041149A3 (en) | 2001-05-02 |
AU709586B2 (en) | 1999-09-02 |
NO971868L (no) | 1997-06-24 |
AU3968395A (en) | 1996-05-15 |
CA2203504A1 (en) | 1996-05-02 |
EP1041149B1 (en) | 2007-07-04 |
PL320214A1 (en) | 1997-09-15 |
BR9509903A (pt) | 1997-11-25 |
EP1041149A2 (en) | 2000-10-04 |
JP3914484B2 (ja) | 2007-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO323305B1 (no) | Opploselig rekombinant botulinum-toksin og farmasoytisk preparat som inneholder det. | |
US6967088B1 (en) | Soluble recombinant botulinum toxin proteins | |
US5919665A (en) | Vaccine for clostridium botulinum neurotoxin | |
US6613329B1 (en) | Vaccine and antitoxin for treatment and prevention of C. difficile disease | |
US5814477A (en) | Recombinant clostridial toxin protein | |
WO1998008540A1 (en) | Multivalent vaccine for clostridium botulinum neurotoxin | |
KR100497700B1 (ko) | 용해성재조합보툴리누스독소단백질 | |
AU2002317523B2 (en) | Vaccine for Clostridium Botulinum Neurotoxin | |
AU747841B2 (en) | Vaccine and antitoxin for treatment and prevention of C. difficile disease | |
CA2416318A1 (en) | Soluble, recombinant botulinum toxin proteins | |
AU2521600A (en) | Treatment for verotoxin-producing escherichia coli |